Cheat sheet

DHA Pharmacist Exam Cheat Sheet

Practice this exam

Toxicology

  • Not published of exam
  • Antidotes Toxidromes Decontamination Overdose Triage

Medicinal Chemistry

  • Not published of exam
  • Structure Activity Ionization Antimicrobials Stereochemistry

Sterile & Nonsterile Compounding

  • Not published of exam
  • Aseptic Technique Sterile Preparations Nonsterile Methods Compatibility

Pharmaceutics & Biopharmaceutics

  • Not published of exam
  • Dosage Forms BCS Classes Dissolution Modified Release

Pharmacognosy & Dietary Supplements

  • Not published of exam
  • Herb Interactions Supplement Safety Natural Products Patient Disclosure

Pharmacy Calculations & Compounding

  • Not published of exam
  • Concentrations Dose Calculations Infusion Rates Renal Estimates

Clinical Pharmacogenomics

  • Not published of exam
  • Gene Drug Pairs Metabolizer Status HLA Risk Dose Selection

Infection Control

  • Not published of exam
  • Hand Hygiene Injection Safety Sharps Clean Preparation

Pharmacokinetics

  • Not published of exam
  • ADME Half-Life Clearance Distribution

Pharmaceutical Care & Disease Management

  • Not published of exam
  • Medication Review Disease Management Counseling Monitoring

Medication Safety

  • Not published of exam
  • Five Rights Reconciliation High Alert Error Prevention

Over-the-Counter Medication

  • Not published of exam
  • Self Care Triage Red Flags Referral Product Selection

Pharmacy Law & Ethics

  • Not published of exam
  • UAE Pharmacy Law Confidentiality Controlled Medicines Professional Ethics

Clinical Pharmacology & Therapeutic Decisions

  • Not published of exam
  • Receptors Dose Response Interactions Therapeutic Choices

Quick Facts

  • Exam DHA Pharmacist PHO5481
  • Authority Dubai Health Authority
  • Delivery Prometric CBT
  • Format Multiple-choice questions
  • Questions 150 questions
  • Duration 3 hours
  • Pass Score 60%
  • Assessment Fee USD 240
  • Result Pass/Fail; score withheld
  • Coverage Areas 14 published topics
  • Domain Weights Not published
  • Attempt Limit Three across UAE authorities
  • Retake Wait No DHA grace period
  • Licensing Portal Sheryan

Poisoning Response Picker TO

  • Patient unstable → ABCs first ( Activate emergency response )
  • Exposure suspected → Toxicology guidance ( Contact local service )
  • History available → Agent-dose-time ( Include formulation )
  • Initial assessment → Vitals, ECG, glucose ( Check temperature )
  • Unknown ingestion → Supportive care ( Avoid blind antidotes )
  • Decontamination considered → Toxicology protocol ( Never induce emesis )
  • Specific indication → Appropriate antidote ( Check contraindications )
  • Symptoms improve → Continue monitoring ( Watch delayed toxicity )

Antidote Map TO

  • Paracetamol N-acetylcysteine
  • Opioids Naloxone
  • Organophosphates Atropine + pralidoxime
  • TCA cardiotoxicity Sodium bicarbonate
  • Methanol/ethylene glycol Fomepizole
  • Iron Deferoxamine
  • Digoxin Digoxin immune Fab
  • Heparin Protamine sulfate
  • Warfarin Vitamin K; PCC for emergencies
  • Methemoglobinemia Methylene blue; check G6PD

Toxidromes & First Response TO

  • Opioid toxidrome Miosis, respiratory depression, coma
  • Anticholinergic Hot, dry, dilated, delirious
  • Cholinergic Secretions, bradycardia, bronchospasm
  • Sympathomimetic Agitation, diaphoresis, tachycardia
  • Serotonin syndrome Clonus, hyperreflexia, hyperthermia
  • Neuroleptic malignant syndrome Rigidity, hyporeflexia, hyperthermia
  • First priority ABCs and emergency support
  • Activated charcoal Selected early ingestions
  • Induced emesis Never routine
  • Poison guidance Contact local toxicology service

Structure-Activity Clues ME

  • pKa Ionization depends on environmental pH
  • Unionized drug Crosses lipid membranes more readily
  • Lipophilicity Often increases membrane penetration
  • Beta-lactam ring Binds PBPs; blocks cross-linking
  • Sulfonamides PABA pathway antagonists
  • Fluoroquinolones Inhibit gyrase/topoisomerase IV
  • Macrolides Bind bacterial 50S ribosome
  • Aminoglycosides Bind bacterial 30S ribosome
  • Stereoisomers Configuration may change activity
  • Prodrug Activation creates active moiety

Sterile vs Nonsterile Compounding CO

Sterile

  • Aseptic environment required
  • Critical sites protected

Nonsterile

  • Clean technique required
  • Uniformity remains essential
  • Route drives sterility need

Compounding Essentials CO

  • Aseptic technique Prevents microbial contamination
  • Critical site Never touch or obstruct
  • HEPA filter Removes airborne particles
  • Unidirectional airflow Sweeps contaminants away
  • LAFW Nonhazardous product protection
  • BSC Hazardous sterile product containment
  • Geometric dilution Incrementally mixes unequal amounts
  • Levigation Smooths powder with liquid
  • Trituration Grinds and mixes powders
  • Aliquot method Measures tiny quantities indirectly
  • Eutectic pair May liquefy when mixed
  • Final label Strength, route, storage, BUD

Pharmaceutics Essentials PH

  • BCS Class I High solubility, high permeability
  • BCS Class II Low solubility, high permeability
  • BCS Class III High solubility, low permeability
  • BCS Class IV Low solubility, low permeability
  • Smaller particles Usually dissolve faster
  • Higher surface area Usually accelerates dissolution
  • Enteric coating Delays release until intestine
  • Modified release Avoid crushing unless approved
  • Suspension Shake before measuring
  • Emulsion Two immiscible liquid phases
  • Surfactant Lowers interfacial tension
  • First-pass effect Lowers systemic bioavailability

Supplement Interaction Flags PH

  • St John's wort Induces CYP3A4 and P-gp
  • Ginkgo May increase bleeding
  • Garlic supplements May increase bleeding
  • Ginseng May lower glucose
  • Licorice May raise BP, lower potassium
  • Kava Hepatotoxicity and sedation concern
  • Valerian May add sedation
  • Grapefruit Inhibits intestinal CYP3A4
  • Natural label Does not guarantee safety
  • Supplement history Ask product, dose, frequency
  • Interaction action Check before recommending
  • Pregnancy Avoid unverified herbal products

Calculation Safety CA

  • Units first, estimate, calculate, verify
  • Align units Estimate answer Calculate once Verify plausibility

Calculation Picker CA

  • Need dose volume → Dose / concentration ( Align units first )
  • Need dilution volume → C1V1 = C2V2 ( Same concentration units )
  • Weight-based order → mg/kg × kg ( Check dose maximum )
  • BSA-based order → mg/m² × BSA ( Verify BSA units )
  • Pump infusion → mL / hours ( Convert time first )
  • Gravity infusion → Drops/min formula ( Use tubing factor )
  • Need rapid target → Loading dose ( Driven by Vd )
  • Need ongoing exposure → Maintenance dose ( Driven by clearance )

Calculation Formulae CA

  • Dose volume Ordered dose / concentration
  • C1V1 = C2V2 Dilution equation
  • % w/v Grams per 100 mL
  • % v/v Milliliters per 100 mL
  • 1:x w/v One gram per x mL
  • mg/kg dose Dose factor × weight
  • BSA dose mg/m² × BSA
  • Infusion rate Volume / hours
  • Drops/min Volume × drop factor / minutes
  • Quantity dispensed Dose × frequency × days
  • Loading dose Target concentration × Vd / F
  • Maintenance rate Target concentration × clearance / F
  • Cockcroft-Gault (140−age) × kg / (72 × SCr)
  • Female CG factor Multiply estimate by 0.85
  • Dimensional analysis Cancel units before calculating
  • Final check Units, plausibility, rounding

Gene-Drug Pairs PH

  • CYP2C19 poor metabolizer Reduced clopidogrel activation
  • HLA-B*57:01 Abacavir hypersensitivity risk
  • HLA-B*15:02 Carbamazepine SJS/TEN risk
  • TPMT/NUDT15 Thiopurine myelotoxicity risk
  • DPYD variant Fluoropyrimidine toxicity risk
  • UGT1A1 reduced function Irinotecan toxicity risk
  • CYP2D6 ultrarapid Codeine toxicity risk
  • CYP2D6 poor Reduced codeine activation
  • SLCO1B1 variant Statin myopathy risk
  • VKORC1/CYP2C9 Warfarin dose sensitivity
  • Genotype result Interpret with phenotype
  • Clinical action Follow current prescribing guidance

Infection Control Essentials IN

  • Before aseptic task Perform hand hygiene
  • Visible soil Use soap and water
  • Clean hands Alcohol rub often preferred
  • Gloves Never replace hand hygiene
  • Preparation area Keep designated and clean
  • Single-dose vial One patient only
  • Needle and syringe One patient, one use
  • Every vial entry Use new needle and syringe
  • Vial septum Disinfect before entry
  • Multidose vial Dedicate when possible
  • Used sharps Discard immediately
  • Insulin pen One patient only

ADME PH

  • Absorb, distribute, metabolize, eliminate
  • A = absorption D = distribution M = metabolism E = elimination

Loading vs Maintenance Dose PH

Loading

  • Reaches target quickly
  • Driven mainly by Vd

Maintenance

  • Replaces eliminated drug
  • Driven mainly by clearance
  • Vd loads; clearance maintains

Pharmacokinetic Core PH

  • Absorption Entry into systemic circulation
  • Bioavailability F Systemically available fraction
  • Vd Amount in body / concentration
  • Clearance Elimination rate / concentration
  • Half-life 0.693 × Vd / clearance
  • Steady state Usually four to five half-lives
  • Loading dose driver Volume of distribution
  • Maintenance dose driver Clearance
  • First-order elimination Constant fraction per time
  • Zero-order elimination Constant amount per time
  • Enzyme induction Often lowers substrate exposure
  • Enzyme inhibition Often raises substrate exposure
  • Renal impairment Often reduces drug clearance

PK Dose Drivers PH

  • Volume loads; clearance maintains
  • Loading = Vd Maintenance = clearance Half-life uses both

First-Order vs Zero-Order PH

First-Order

  • Constant fraction eliminated
  • Half-life usually constant

Zero-Order

  • Constant amount eliminated
  • Pathway capacity saturated
  • Fraction versus amount

IESA Medication Review PH

  • Indication, effectiveness, safety, adherence
  • I = needed E = working S = safe A = taken

Pharmaceutical Care Review PH

  • Unnecessary therapy No valid indication
  • Additional therapy Untreated condition or prevention
  • Ineffective therapy Wrong medicine or formulation
  • Dose too low Insufficient exposure or frequency
  • Adverse reaction Medicine causes harmful response
  • Dose too high Excess exposure or frequency
  • Nonadherence Regimen not followed
  • Interaction screen Drug, food, disease
  • Renal function Adjust medicine and interval
  • Treatment goal Define measurable patient outcome
  • Teach-back Confirms patient understanding
  • Follow-up Reassess outcome and safety

Five Rights ME

  • Patient, drug, dose, route, time
  • Right patient Right drug Right dose Right route Right time

Allergy vs Side Effect ME

Allergy

  • Immune-mediated reaction
  • May preclude re-exposure

Side Effect

  • Known pharmacologic effect
  • May be manageable
  • Document reaction details

Medication Error Response ME

  • Error intercepted → Stop process ( Prevent administration )
  • Exposure possible → Assess patient ( Stabilize first )
  • Harm suspected → Escalate immediately ( Follow emergency protocol )
  • Treatment needed → Notify prescriber ( Use verified facts )
  • Patient affected → Follow disclosure policy ( Communicate transparently )
  • Immediate risk controlled → Report event ( Include near misses )
  • Record required → Document objectively ( Avoid blame )
  • Review completed → Add system control ( Prevent recurrence )

Medication Safety Controls ME

  • Right patient Use two identifiers
  • Right drug Verify product and label
  • Right dose Calculate and range-check
  • Right route Verify form and compatibility
  • Right time Check schedule and interactions
  • Allergy check Verify before dispensing
  • Reconciliation Compare complete medication lists
  • High-alert medicine Use independent double-check
  • Look-alike names Separate and use Tall Man
  • Leading zero Write 0.5 mg
  • Trailing zero Never write 5.0 mg
  • Oral liquid Use oral syringe
  • Near miss Report and analyze
  • Barcode Does not replace vigilance
  • Medication error Protect patient first

Medication Error vs Adverse Reaction ME

Medication Error

  • Preventable process failure
  • May cause no harm

Adverse Reaction

  • Harmful medicine response
  • May occur correctly used
  • Classify before reporting

WWHAM Self-Care OT

  • Who, what, how long, actions, medicines
  • Who is it What symptoms How long Actions tried Medicines used

OTC Triage Picker OT

  • Emergency symptoms → Emergency pathway ( Do not delay )
  • Serious red flag → Urgent referral ( Avoid masking symptoms )
  • Pregnant or breastfeeding → Verify safety ( Consider trimester )
  • Very young child → Age-specific pathway ( Check local limits )
  • Major comorbidity → Interaction check ( Renal, hepatic, cardiac )
  • Duplicate ingredients → Simplify product ( Prevent overdose )
  • Mild self-limited problem → Short self-care trial ( Give stop rules )
  • Persistent or worsening → Clinical referral ( Reassess diagnosis )

OTC Referral Flags OT

  • Chest pain Emergency evaluation
  • Severe dyspnea Emergency evaluation
  • Anaphylaxis signs Emergency treatment
  • GI bleeding signs Urgent referral
  • Severe dehydration Urgent referral
  • Young infant fever Follow urgent local pathway
  • Pregnancy/lactation Verify product safety
  • Renal/hepatic disease Check before self-care
  • Persistent symptoms Refer for assessment
  • Worsening symptoms Stop self-care; refer
  • Oral decongestant Caution uncontrolled hypertension
  • NSAID Check GI, renal, bleeding risks
  • Combination product Check duplicate ingredients
  • Self-care advice Give duration and stop rules

Pharmacist vs Clinical Pharmacy LA

Pharmacist

  • Code PHO5481
  • Pass score 60%
  • This sheet's target

Clinical Pharmacy

  • Code PHO5482
  • Pass score 70%
  • Separate DHA assessment
  • Match title and code

DHA Licensing Path LA

  • Starting application → Self-Assessment Tool ( Check PQR eligibility )
  • Credentials accepted → Primary source verification ( DataFlow process )
  • CBT required → Prometric assessment ( Use eligibility ID )
  • Requirements completed → Get Registered ( DHA reviews application )
  • Registration issued → Find licensed facility ( Cannot practice yet )
  • Facility hires → Activate license ( Facility completes activation )
  • License active → Practice within scope ( Follow DHA requirements )
  • Expiry approaches → Renew timely ( Maintain requirements )

UAE Law & Ethics LA

  • Dubai regulator Dubai Health Authority
  • Practice permission Active professional license
  • Registration Eligibility before license activation
  • License activation Completed by hiring facility
  • Professional scope Stay within licensed activity
  • Confidentiality Protect patient information
  • Professional duty Accuracy, honesty, patient welfare
  • Controlled possession Requires legal authorization
  • Controlled dispensing Only legally permitted cases
  • Controlled prescription Record on national platform
  • Federal law text Original Arabic controls
  • Local procedure Follow authority and facility rules

Registration vs Active License LA

Registration

  • Confirms title eligibility
  • Precedes facility activation

Active License

  • Permits professional practice
  • Activated by hiring facility
  • Registration alone forbids practice

Prescription vs Controlled Medicine LA

Prescription Medicine

  • Requires valid prescription
  • Standard records apply

Controlled Medicine

  • Additional legal restrictions
  • National tracking applies
  • Controlled rules are stricter

Potency vs Efficacy CL

Potency

  • Dose needed
  • Reflected by EC50

Efficacy

  • Maximum effect
  • Reflected by Emax
  • More potent is not stronger

Interaction Checker CL

  • Two agents flagged → Identify perpetrator ( And affected substrate )
  • Concentration changes → PK mechanism ( ADME interaction )
  • Effects combine → PD mechanism ( Bleeding, sedation, QT )
  • Timing may help → Separate administration ( Only when evidence supports )
  • Patient risk high → Avoid combination ( Choose alternative )
  • Combination necessary → Monitor or adjust ( Define measurable endpoint )
  • Plan selected → Counsel patient ( Give warning signs )
  • Action completed → Document rationale ( Arrange follow-up )

Pharmacodynamics Core CL

  • Agonist Activates receptor response
  • Antagonist Blocks receptor activation
  • Partial agonist Lower maximal receptor response
  • Potency Dose needed for effect
  • Efficacy Maximum achievable effect
  • Affinity Binding strength at receptor
  • EC50 Concentration producing half-maximal effect
  • Competitive antagonist Shifts dose-response right
  • Noncompetitive antagonist Lowers maximal effect
  • Therapeutic index Toxic dose / effective dose
  • Additive effect Combined effects sum
  • Synergistic effect Combined effect exceeds sum
  • Tolerance Response decreases over time
  • Tachyphylaxis Rapidly developing tolerance

Bactericidal vs Bacteriostatic CL

Bactericidal

  • Kills susceptible bacteria
  • Clinical effect remains context-dependent

Bacteriostatic

  • Inhibits bacterial growth
  • Host defenses aid clearance
  • Label alone never chooses therapy

Clinical Therapy Alerts CL

  • ACE inhibitor Cough, hyperkalemia, angioedema
  • ACEI pregnancy Contraindicated
  • Beta blocker Bradycardia; masks hypoglycemia
  • Loop diuretic Hypokalemia and volume depletion
  • Spironolactone Hyperkalemia risk
  • NSAID GI, renal, fluid risks
  • Statin Myopathy and interaction check
  • Warfarin INR and interaction monitoring
  • DOAC Renal function affects dosing
  • Insulin Hypoglycemia risk
  • Sulfonylurea Hypoglycemia risk
  • Metformin Renal function limits use
  • Aminoglycoside Nephrotoxicity and ototoxicity
  • Lithium Monitor level, renal, thyroid
  • Chronic corticosteroid Do not stop abruptly
  • Antimicrobial choice Site, culture, allergy, renal

Common Traps

Invented Blueprint Weights

  • DHA lists 14 areas ≠ DHA publishes no percentages

Wrong Pharmacist Code

  • PHO5481 is Pharmacist ≠ PHO5482 is Clinical Pharmacy

Score Report Assumption

  • Result is Pass/Fail ≠ Numeric score is withheld

Registration Confusion

  • Registration confirms eligibility ≠ Active license permits practice

Attempt Rule Confusion

  • Maximum three across authorities ≠ No DHA retake grace period

Strength Conversion Error

  • 1% w/v = 10 mg/mL ≠ Convert units before calculating

Unsafe Decimal

  • Use leading zero ≠ Never use trailing zero

Modified-Release Damage

  • Do not crush routinely ≠ Verify product instructions

Glove Substitution

  • Gloves reduce exposure ≠ Hand hygiene remains required

Natural Means Safe

  • Supplements cause interactions ≠ Always collect supplement history

Allergy Mislabeling

  • Allergy is immune-mediated ≠ Side effect may be predictable

Antidote-Only Thinking

  • ABCs come first ≠ Supportive care remains essential

Last Minute

  • 1. PHO5481 = DHA Pharmacist
  • 2. PHO5482 = Clinical Pharmacy
  • 3. 150 questions in 3 hours
  • 4. PHO5481 pass score is 60%
  • 5. Assessment fee is USD 240
  • 6. Official coverage has 14 areas
  • 7. Domain weights are not published
  • 8. Results report Pass/Fail only
  • 9. Three attempts across UAE authorities
  • 10. No DHA retake grace period
  • 11. Registration is not active licensure
  • 12. Facility activates professional license
  • 13. C1V1 equals C2V2 for dilutions
  • 14. Loading dose follows Vd
  • 15. Maintenance dose follows clearance
  • 16. Steady state needs several half-lives
  • 17. Always align calculation units
  • 18. Use leading, never trailing zeros
  • 19. Gloves never replace hand hygiene
  • 20. One syringe serves one patient
  • 21. Check renal function before dosing
  • 22. Natural products still interact
  • 23. OTC red flags require referral
  • 24. Poisoning starts with ABCs
  • 25. Controlled medicines need stricter records
  • 26. Follow current local clinical protocols

DHA Pharmacist Licensing Assessment

  • Practice Questions 125 questions Study Guide 63 topics Cheat Sheet 202 facts Flashcards 50 cards Shorts 1 short Podcast

Same family resources

  • Explore More Gulf Pharmacist Licensing Exams
  • Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Saudi Pharmacist Licensure Examination (SPLE - Pharmacist)

  • Cheat Sheet 83 facts Practice Questions 100 questions Study Guide 42 topics Flashcards 50 cards

Kuwait MOH Licensing Examination - Pharmacist

  • Practice Questions 125 questions Shorts 1 short

DOH Abu Dhabi Pharmacist Qualification Exam

  • Practice Questions 100 questions

MOHAP Pharmacist Evaluation Exam

  • Practice Questions 100 questions

NHRA Licensure Examination - Pharmacist

  • Practice Questions 100 questions Shorts 1 short

OMSB Licensing Examination - Pharmacist

  • Practice Questions 100 questions